European Society of Breast Imaging (EUSOBI) guidelines on the management of axillary lymphadenopathy after COVID-19 vaccination: 2023 revision

4Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Axillary lymphadenopathy is a common side effect of COVID-19 vaccination, leading to increased imaging-detected asymptomatic and symptomatic unilateral axillary lymphadenopathy. This has threatened to negatively impact the workflow of breast imaging services, leading to the release of ten recommendations by the European Society of Breast Imaging (EUSOBI) in August 2021. Considering the rapidly changing scenario and data scarcity, these initial recommendations kept a highly conservative approach. As of 2023, according to newly acquired evidence, EUSOBI proposes the following updates, in order to reduce unnecessary examinations and avoid delaying necessary examinations. First, recommendation n. 3 has been revised to state that breast examinations should not be delayed or rescheduled because of COVID-19 vaccination, as evidence from the first pandemic waves highlights how delayed or missed screening tests have a negative effect on breast cancer morbidity and mortality, and that there is a near-zero risk of subsequent malignant findings in asymptomatic patients who have unilateral lymphadenopathy and no suspicious breast findings. Second, recommendation n. 7 has been revised to simplify follow-up strategies: in patients without breast cancer history and no imaging findings suspicious for cancer, symptomatic and asymptomatic imaging-detected unilateral lymphadenopathy on the same side of recent COVID-19 vaccination (within 12 weeks) should be classified as a benign finding (BI-RADS 2) and no further work-up should be pursued. All other recommendations issued by EUSOBI in 2021 remain valid. Graphical abstract: [Figure not available: see fulltext.]

References Powered by Scopus

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

10859Citations
N/AReaders
Get full text

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

7599Citations
N/AReaders
Get full text

The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada

138Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Understanding BI-RADS Category 3

1Citations
N/AReaders
Get full text

Emerging complications in the era of COVID-19 vaccination: role of radiologists and imaging

0Citations
N/AReaders
Get full text

Vaccine-associated axillary lymphadenopathy with a focus on COVID-19 vaccines

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Schiaffino, S., Pinker, K., Cozzi, A., Magni, V., Athanasiou, A., Baltzer, P. A. T., … Pijnappel, R. M. (2023). European Society of Breast Imaging (EUSOBI) guidelines on the management of axillary lymphadenopathy after COVID-19 vaccination: 2023 revision. Insights into Imaging, 14(1). https://doi.org/10.1186/s13244-023-01453-2

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

69%

Professor / Associate Prof. 2

15%

Researcher 2

15%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

60%

Nursing and Health Professions 4

27%

Physics and Astronomy 1

7%

Engineering 1

7%

Save time finding and organizing research with Mendeley

Sign up for free